Serotonin syndrome following left ventricular assist device implantation: A report and institution-specific strategy for prevention.
Publication/Presentation Date
12-1-2019
Abstract
Serotonin syndrome is a potentially lethal complication of antidepressant therapy. Cardiac surgical patients are at particularly high risk of serotonin syndrome due to the prevalence of depression in patients with advanced cardiac disease, many of whom receive multiple serotonergic agents in the perioperative period. Here, we describe a case of postoperative serotonin syndrome following methylene blue administration for perioperative vasoplegia during left ventricular assist device implantation. We additionally describe an institution-specific strategy to minimize future occurrences of serotonin syndrome in this high-risk population.
Volume
20
Issue
6
First Page
218
Last Page
220
ISSN
1878-5409
Published In/Presented At
Katzianer, D., Chism, K., Qureshi, A. M., Watson, R., Massey, H. T., Boyle, A. J., Reeves, G., & Danelich, I. (2019). Serotonin syndrome following left ventricular assist device implantation: A report and institution-specific strategy for prevention. Journal of cardiology cases, 20(6), 218–220. https://doi.org/10.1016/j.jccase.2019.09.004
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31762837
Department(s)
Administration and Leadership
Document Type
Article